Therefore, anti-IL-6 therapy may be considered for critically ill patients who meet all of the following criteria: IL-6 levels ≥ 100 pg/mL, predicted mortality > 40%, concurrent sepsis, and neutropenia. Here, IL6 is linked to Decreased total neutrophil count.